Calciprotein particles (CPP) at baseline and after 96 weeks, with between-group differences
| . | Baseline . | Week 96 . | Treatment effect versus placebo at Week 96 . | . | ||
|---|---|---|---|---|---|---|
| . | N . | Median (IQR) . | N . | Median (IQR) . | % change (95% CI) . | P-value . |
| CPP-I (×104 particles/mL) | ||||||
| Placebo | 127 | 16.3 (6.5–59.7) | 99 | 17.6 (6.0–54.8) | – | – |
| Lanthanum | 12.4 (3.7–48.5) | 15.2 (4.6–35.8) | 22.8 (−39.2, 36.4) | 0.648 | ||
| CPP-II (×103 particles/mL) | ||||||
| Placebo | 126 | 3.8 (1.5–5.8) | 99 | 3.5 (1.3–5.8) | – | – |
| Lanthanum | 3.0 (1.3–5.1) | 2.6 (1.0–4.0) | −18.3 (−40.0, 11.2) | 0.198 | ||
| . | Baseline . | Week 96 . | Treatment effect versus placebo at Week 96 . | . | ||
|---|---|---|---|---|---|---|
| . | N . | Median (IQR) . | N . | Median (IQR) . | % change (95% CI) . | P-value . |
| CPP-I (×104 particles/mL) | ||||||
| Placebo | 127 | 16.3 (6.5–59.7) | 99 | 17.6 (6.0–54.8) | – | – |
| Lanthanum | 12.4 (3.7–48.5) | 15.2 (4.6–35.8) | 22.8 (−39.2, 36.4) | 0.648 | ||
| CPP-II (×103 particles/mL) | ||||||
| Placebo | 126 | 3.8 (1.5–5.8) | 99 | 3.5 (1.3–5.8) | – | – |
| Lanthanum | 3.0 (1.3–5.1) | 2.6 (1.0–4.0) | −18.3 (−40.0, 11.2) | 0.198 | ||
Change in calciprotein particles (CPP) compared with baseline, estimated from mixed effects models with repeated measurements. Models were fitted to natural log transformed data in order to ensure normal distribution of residuals; thereafter the regression coefficients have been exponentiated into percentage change to aid interpretation.
Calciprotein particles (CPP) at baseline and after 96 weeks, with between-group differences
| . | Baseline . | Week 96 . | Treatment effect versus placebo at Week 96 . | . | ||
|---|---|---|---|---|---|---|
| . | N . | Median (IQR) . | N . | Median (IQR) . | % change (95% CI) . | P-value . |
| CPP-I (×104 particles/mL) | ||||||
| Placebo | 127 | 16.3 (6.5–59.7) | 99 | 17.6 (6.0–54.8) | – | – |
| Lanthanum | 12.4 (3.7–48.5) | 15.2 (4.6–35.8) | 22.8 (−39.2, 36.4) | 0.648 | ||
| CPP-II (×103 particles/mL) | ||||||
| Placebo | 126 | 3.8 (1.5–5.8) | 99 | 3.5 (1.3–5.8) | – | – |
| Lanthanum | 3.0 (1.3–5.1) | 2.6 (1.0–4.0) | −18.3 (−40.0, 11.2) | 0.198 | ||
| . | Baseline . | Week 96 . | Treatment effect versus placebo at Week 96 . | . | ||
|---|---|---|---|---|---|---|
| . | N . | Median (IQR) . | N . | Median (IQR) . | % change (95% CI) . | P-value . |
| CPP-I (×104 particles/mL) | ||||||
| Placebo | 127 | 16.3 (6.5–59.7) | 99 | 17.6 (6.0–54.8) | – | – |
| Lanthanum | 12.4 (3.7–48.5) | 15.2 (4.6–35.8) | 22.8 (−39.2, 36.4) | 0.648 | ||
| CPP-II (×103 particles/mL) | ||||||
| Placebo | 126 | 3.8 (1.5–5.8) | 99 | 3.5 (1.3–5.8) | – | – |
| Lanthanum | 3.0 (1.3–5.1) | 2.6 (1.0–4.0) | −18.3 (−40.0, 11.2) | 0.198 | ||
Change in calciprotein particles (CPP) compared with baseline, estimated from mixed effects models with repeated measurements. Models were fitted to natural log transformed data in order to ensure normal distribution of residuals; thereafter the regression coefficients have been exponentiated into percentage change to aid interpretation.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
